{"id":"bopv","safety":{"commonSideEffects":[{"rate":null,"effect":"Vaccine-derived poliovirus (VDPV) shedding"},{"rate":null,"effect":"Mild gastrointestinal symptoms"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"bOPV (bivalent oral polio vaccine) delivers weakened forms of poliovirus serotypes 1 and 3 orally, stimulating both intestinal mucosal immunity (IgA) and systemic humoral immunity (IgG). This dual immune response prevents infection and transmission of wild poliovirus in the gastrointestinal tract. The vaccine is part of global polio eradication initiatives, particularly in regions where type 2 poliovirus has been eliminated.","oneSentence":"bOPV is an oral polio vaccine containing live attenuated poliovirus types 1 and 3 that induces mucosal and systemic immunity against poliomyelitis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:28.114Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis caused by poliovirus types 1 and 3"}]},"trialDetails":[{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT06137664","phase":"PHASE1, PHASE2","title":"Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines","status":"RECRUITING","sponsor":"PATH","startDate":"2024-11-20","conditions":"Poliomyelitis","enrollment":2400},{"nctId":"NCT06920069","phase":"PHASE4","title":"Study of Concomitant Administration of the sIPV and DTaP or MMR","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2025-05-15","conditions":"Polio, Diphteria, Tetanus and Pertussis, MMR Vaccine","enrollment":2640},{"nctId":"NCT05431933","phase":"PHASE3","title":"Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants","status":"COMPLETED","sponsor":"LG Chem","startDate":"2023-01-10","conditions":"Poliomyelitis, Vaccine Reaction","enrollment":2001},{"nctId":"NCT06752174","phase":"PHASE3","title":"A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants","status":"COMPLETED","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2023-03-08","conditions":"Poliomyelitis","enrollment":300},{"nctId":"NCT06748612","phase":"PHASE4","title":"Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-01-28","conditions":"Polio","enrollment":1190},{"nctId":"NCT04579510","phase":"PHASE2","title":"Immunogenicity nOPV2 With and Without bOPV","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2021-02-08","conditions":"Poliomyelitis","enrollment":795},{"nctId":"NCT05677256","phase":"PHASE4","title":"A Study to Evaluate Pharyngeal Immunity to Poliovirus Type-2","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2023-11-09","conditions":"Poliomyelitis","enrollment":500},{"nctId":"NCT03554798","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2018-12-04","conditions":"Poliomyelitis","enrollment":1025},{"nctId":"NCT06114810","phase":"PHASE4","title":"Immunogenicity of Novel Oral Poliovirus Vaccine Type 2 (nOPV2), bOPV and IPV","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2023-11","conditions":"Polio","enrollment":880},{"nctId":"NCT03614702","phase":"PHASE3","title":"Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2015-09-15","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT04232943","phase":"PHASE1","title":"Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults","status":"COMPLETED","sponsor":"PATH","startDate":"2020-01-22","conditions":"Polio","enrollment":87},{"nctId":"NCT03581734","phase":"PHASE3","title":"Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2018-07-01","conditions":"Vaccine Reaction","enrollment":579},{"nctId":"NCT04576910","phase":"PHASE4","title":"Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China","status":"COMPLETED","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2020-11-05","conditions":"Polio, Vaccine Reaction","enrollment":387},{"nctId":"NCT05166031","phase":"PHASE3","title":"Evaluation of the Immunogenicity and Safety of Concomitant Administration of Novel Oral Polio Type 2 Vaccine and Bivalent Oral Polio Vaccine","status":"WITHDRAWN","sponsor":"Fidec Corporation","startDate":"2020-12","conditions":"Poliomyelitis","enrollment":""},{"nctId":"NCT03722004","phase":"PHASE4","title":"Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2018-12-18","conditions":"Poliomyelitis","enrollment":1256},{"nctId":"NCT01908114","phase":"PHASE4","title":"To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Intervention Package for Polio Eradication in Pakistan","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2013-07","conditions":"Polio, Polio Sero Conversion, Polio Sero Prevalence","enrollment":60000},{"nctId":"NCT01229579","phase":"NA","title":"Effect of Zinc Supplementation on Response to Oral Polio Vaccine in Infants in Pakistan","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2010-05","conditions":"Poliomyelitis","enrollment":320},{"nctId":"NCT03202719","phase":"PHASE4","title":"Duration of IPV Priming and Antibody Decay","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2017-11-05","conditions":"Poliomyelitis","enrollment":1645},{"nctId":"NCT02521974","phase":"PHASE4","title":"A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2015-10","conditions":"Adverse Event Following Immunisation","enrollment":164},{"nctId":"NCT04504539","phase":"NA","title":"Use of mOPV1 in Routine Immunization in Pakistan.","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2020-08","conditions":"Oral Polio Vaccine","enrollment":560},{"nctId":"NCT02434770","phase":"PHASE3","title":"Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2015-08","conditions":"Poliomyelitis","enrollment":750},{"nctId":"NCT03147560","phase":"PHASE4","title":"Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants","status":"COMPLETED","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2017-05-02","conditions":"Polio","enrollment":528},{"nctId":"NCT04054492","phase":"PHASE4","title":"To Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2018-03-01","conditions":"Vaccination, Reaction - Vaccine","enrollment":604},{"nctId":"NCT02766816","phase":"PHASE3","title":"A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals","status":"COMPLETED","sponsor":"Bilthoven Biologicals","startDate":"2016-06-08","conditions":"Immune Response to Oral Polio Vaccine","enrollment":1120},{"nctId":"NCT03822767","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a \"2+1\"Sequential Schedule With bOPV in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-06-12","conditions":"Poliomyelitis","enrollment":240},{"nctId":"NCT03822754","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-06-06","conditions":"Poliomyelitis","enrollment":240},{"nctId":"NCT03821441","phase":"PHASE3","title":"Trail To Evaluate the Immune Effects of Primary and Booster Immunizations With Poliovirus Vaccine","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2018-01-04","conditions":"Poliomyelitis","enrollment":1165},{"nctId":"NCT03310073","phase":"PHASE4","title":"Immunogenicity and Safety Profile of Primary Dose of bOPV Bio Farma Given Simultaneously With Pentabio And IPV","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2016-07","conditions":"Healthy","enrollment":143},{"nctId":"NCT02477046","phase":"PHASE3","title":"Assessment of Community Transmission of Sabin Type 2 Virus in Bangladesh","status":"UNKNOWN","sponsor":"University of Virginia","startDate":"2015-04","conditions":"Vaccine Virus Shedding","enrollment":810},{"nctId":"NCT02412514","phase":"PHASE4","title":"Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2015-04","conditions":"Poliomyelitis","enrollment":456},{"nctId":"NCT02785705","phase":"PHASE3","title":"Randomized Controlled Trial for Immunogenicity and Safety Evaluation of Bivalent Types 1 and 3 Oral Poliovirus Vaccine","status":"COMPLETED","sponsor":"Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control","startDate":"2015-04","conditions":"Poliomyelitis","enrollment":600},{"nctId":"NCT02189811","phase":"PHASE4","title":"Polio End-game Strategies - Poliovirus Type 2 Challenge Study","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2014-09","conditions":"Poliomyelitis","enrollment":900},{"nctId":"NCT01559636","phase":"NA","title":"Diarrhea and Bivalent Oral Polio Vaccine Immunity","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2012-08","conditions":"Seroimmunity, Diarrhea, Polio","enrollment":699},{"nctId":"NCT02291263","phase":"PHASE3","title":"Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2014-10","conditions":"Poliomyelitis","enrollment":738},{"nctId":"NCT01831050","phase":"PHASE4","title":"Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2013-05","conditions":"Poliomyelitis","enrollment":1420},{"nctId":"NCT01586572","phase":"NA","title":"Pakistan Short Interval mOPV1 Compared With Standard Interval mOPV1 and bOPV 1,3","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2012-04","conditions":"Polio","enrollment":1000},{"nctId":"NCT01841671","phase":"PHASE4","title":"Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine","status":"UNKNOWN","sponsor":"University of Chile","startDate":"2013-04","conditions":"Polio","enrollment":570},{"nctId":"NCT01695798","phase":"PHASE4","title":"IPV in Moderate to Severe Chronic Malnourished 9-12 Month Old Children in Karachi.","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2012-10","conditions":"Immunity to Polio Vaccines in Malnourished Infants, Immunity to Polio Vaccines in Non-malnourished Infants","enrollment":840},{"nctId":"NCT01813604","phase":"PHASE3","title":"Immunogenicity of Inactivated and Live Polio Vaccines","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2012-11","conditions":"Poliomyelitis","enrollment":1206},{"nctId":"NCT01633216","phase":"PHASE4","title":"Poliovirus Vaccine Trial in Bangladesh","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2012-05","conditions":"Healthy Infants","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":170,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sanofi bOPV","bivalent Oral Polio Vaccine"],"phase":"marketed","status":"active","brandName":"bOPV","genericName":"bOPV","companyName":"Aga Khan University","companyId":"aga-khan-university","modality":"Biologic","firstApprovalDate":"","aiSummary":"bOPV is an oral polio vaccine containing live attenuated poliovirus types 1 and 3 that induces mucosal and systemic immunity against poliomyelitis. Used for Prevention of poliomyelitis caused by poliovirus types 1 and 3.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}